Replication and Genome Stability Group

Publications

Targeting CDK2 in cancer: challenges and opportunities for therapy

Tadesse, S.; Anshabo, A. T.; Portman, N.; Lim, E.; Tilley, W.; Caldon, C. E.; Wang, S.

DRUG DISCOVERY TODAY 25(2):406-413, 2020

Cyclin E2 induces genomic instability by mechanisms distinct from cyclin E1

Caldon, C.E.; Sergio, C.M.; Burgess, A.; Deans, A.J.; Sutherland, R.L.; Musgrove, E.A.;

CELL CYCLE 12(4):606-617, 2013

Distinct and redundant functions of cyclin E1 and cyclin E2 in development and cancer

Caldon, C. E.; Musgrove, E.A.

Cell Division 5:2, 2010

Estrogen regulation of cyclin E2 requires cyclin D1, but not c-Myc

Caldon, C.E.; Sergio, C.M.; Schutte, J.; Boersma, M.N.; Sutherland, R.L.; Carroll, J.S.; Musgrove, E.A.

MOLECULAR AND CELLULAR BIOLOGY 29(17):4623-4639, 2009

Cdk2 regulates metastasis suppressor BRMS1

Caldon, C. E.;

CELL CYCLE 15(6):779-80, 2016

Cyclin Dependent Kinase 2 inhibitors in cancer therapy: an update

Tadesse, S.; Caldon, E. C.; Tilley, W.; Wang, S.

JOURNAL OF MEDICINAL CHEMISTRY 62(9):4233-4251, 2019

Cell cycle proteins in epithelial cell differentiation: implications for breast cancer

Caldon, C.E., Sutherland, R.L.; Musgrove, E.A.

CELL CYCLE 9(10):1918-1928, 2010

Estrogen signaling and the DNA damage response in hormone dependent breast cancers

Caldon, C. E.;

Frontiers in Oncology 4:106, 2014

Cyclin E2 overexpression is associated with endocrine resistance but not insensitivity to CDK2 inhibition in human breast cancer cells.

Caldon, C.E.; Sergio, C.M.; Kang, J.; Muthukaruppan, A.; Boersma, M.; Stone, A.; Barraclough, J. Lee, C.S.L.; Black, M.A.; Miller, L.D.; Gee, J.M.; Nicholson, R.I.; Sutherland, R.L.; Print, C.G.; Musgrove, E.A.

MOLECULAR CANCER THERAPEUTICS 11(7):1488-99, 2012

Friends and foes: Our evolving understanding of the link between Fbxw7 and p53 in cancer

Caldon, C.E.

NEOPLASIA 22(11):659-660, 2020

Overcoming CDK4/6 inhibitor resistance in ER positive breast cancer

Portman, N.; Alexandrou, S.; Carson, E.; Wang, S.; Lim, E.; Caldon, C. E.

ENDOCRINE-RELATED CANCER 26:R15-R30, 2019

19q12 amplified and non-amplified subsets of high grade serous ovarian cancer with overexpression of cyclin E1 differ in their molecular drivers and clinical outcomes

Aziz, D.; Etemadmoghadam, D.; Caldon, C. E.; Au-Yeung, G.; Deng, N.; Hutchinson, R.; Bowtell, D.; Waring, P.

GYNECOLOGIC ONCOLOGY 151(2):327-336, 2018

Label free, quantitative single-cell fate tracking of time-lapse movies

Caldon, C. E.; Burgess, A.

MethodsX 6:2468-2475, 2019

Differences in degradation lead to asynchronous expression of cyclin E1 and cyclin E2 in cancer cells

Caldon, C. E.; Sergio, C.M.; Sutherland, R.L.; Musgrove, E.A.;

CELL CYCLE 12(4):596-605, 2013

Cyclin E2 promotes whole genome doubling in breast cancer

Lee, C.; Fernandez, K. J.; Alexandrou, S.; Sergio, C. M.; Deng, N.; Rogers, S.; Burgess, A.; Caldon, C. E.

Cancers 12(8):2268, 2020

The proliferative and apoptotic landscape of basal-like breast cancer

Alexandrou, S.; George, S. M.; Ormandy, C. J.; Lim, E.; Oakes, S. R.; Caldon, C. E.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 20(3):667, 2019

Editorial: Proceedings From ACCM19: Cell Cycle, DNA Damage Response and Telomeres

Burgess, A.; Caldon, C. E.

Frontiers in Cell and Developmental Biology 8:805, 2020